Mobilization and selection of CD34-positive hematopoietic progenitors

Blood Reviews

Volumn 10, Issue 1, 1996, Pages 1-7

  Cagnoni, P J ^a   Shpall, E J ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; ETOPOSIDE; INTERLEUKIN 3; MILODISTIM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

AUTOTRANSPLANTATION; BLOOD; BONE MARROW; BREAST CANCER; CELL SELECTION; CLINICAL TRIAL; COLONY FORMING UNIT GM; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKAPHERESIS; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOLID TUMOR; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 0030009646     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(96)90014-4     Document Type: Article

References (69)

1. Armitage JO. Bone Marrow Transplantation. N Engl J Med 1994; 330: 827.
2. Shpall EJ, Jones RB. Release of tumor cells from bone marrow. Blood 1994; 83: 623-625.
3. Haas R, Witt B, Mohle R et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754-3761.
4. Pettengell R, Morgenstern GR, Woll PJ et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993; 82: 3770-3777.
5. + progenitors and colony-forming units-granulocyte macrophage are recruited during large-volume leukapheresis and concentrated by counterflow elutriation. Transfusion 1993; 33: 316-321.
6. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723-727.
7. Williams SF, Bitran JD, Richards JM et al. Peripheral blood-derived stem cell collections for use in autologous transplantation after high-dose chemotherapy: an alternative approach. Bone Marrow Transplant 1990; 5: 129-133.
8. Kessinger A, Armitage JO, Smith DM, Landmark JD, Bierman PJ, Weisenburger D. High-dose therapy and autologous marrow peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260.
9. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-1039.
10. Abrams RA, Johnston-Early A, Kramer C et al. Amplification of circulating granulocyte-monocyte stem cells (CFU-C) numbers following chemotherapy in patients with extensive small cell carcinoma of the lung. Cancer Res 1981; 41: 35-41.
11. Reiffers J, Castaigne S, Tilly H et al. Hematopoietic reconstitution after autologous blood stem cell transplantation a report of 46 cases. Plasma Ther Transfus Technol 1987; 8: 360-364.
12. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
13. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 369.
14. Reiffers J, Faberes C, Commenges D et al. The CD34 assay is not of predictive value for engraftment after PBSC transplantation. Proc 2nd International Symposium on Peripheral Blood Stem Cell Autografts, Mulhouse, France 1991.
15. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194-1198.
16. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant granulocyte colony stimulating factor on hematopoietic progenitor cells in cancer patient. Blood 1988; 72: 2074-2081.
17. Sheridan W, Begley CG, Juttner CA et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 1: 640-644.
18. Peters WP, Rosner G, Ross M, Vredenbirgh J, Meisenberg B, Gilbert C, Kurtzberg J. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
19. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
20. Elias A, Mazanet R, Anderson K et al. GM-CSF mobilized peripheral blood stem cell autografts: the DFCI/BIH experience. Proc 2nd International Symposium on Peripheral Blood Stem Cell Autografts. Mulhouse, France, September - October 1991.
21. Gianni AM, Siena S, Bregni M et al. Granulocyte-macrophage colony stimulating factor to harvest circulating hematopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-586.
22. Haas R, Ho AD, Bredthauer U et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony stimulating factor. Exp Hematol 1990; 18: 94.
23. Spitzer G, Huan SD, Hester J et al. Influence of mobilized peripheral blood cells on the hcmatopoictic recovery from autologous marrow and recombinant granulocyte-macrophage colony stimulating factor (rhGM-CSF) following high-dose cyclophosphamide, etoposide, and cisplatin. Proc 2nd International Symposium on Peripheral Blood Stem Cell Autografts. Mulhouse, France, September - October 1991.
24. Vose JM, Kessinger A, Bierman P, Sharp G, Garrison L, Armitage JO. The use of rh-IL-3 for mobilization of peripheral blood stem cells in previously treated patients with lymphoid malignancies. Proc 2nd International Symposium on Peripheral Blood Stem Cell Autografts. Mulhouse, France, September - October 1991.
25. Glaspy J, McNiece I, LeMaistre F et al. Effects of stem cell factor (rhSCF) and filgrastim (rhG-CSF) on mobilization of peripheral blood progenitor cells (PBPC) and on hematological recovery post-transplant: early results from a phase I/II study. Proc Am Soc Clin Oncol 1994; 13: 68.
26. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
27. Bensinger W, Singer J, Appelbaum F et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 1: 3158-3163.
28. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
29. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390-397.
30. Hara H, Namiki M. Mechanism of synergy between GM-CSF and G-CSF in colony formation from human marrow cells in vitro. Exp Hematol 1989; 17: 816-821.
31. Brucher J, Martin H, Hess U et al. Interleukin-3 combined with rGM-CSF efficiently mobilizes circulating hematopoietic progenitor cells without prior chemotherapy. Proc 2nd International Symposium on Peripheral Blood Stem Cell Autografts. Mulhouse, France, September - October 1991.
32. Andrews RG, Bartelmez SH, Knitter GH et al. A c-kit ligand, recombinant human stem cell factor mediates reversible expansion of CD34+ colony-forming cells types in blood and marrow of baboons. Blood 1992; 80: 920-927.
33. Briddell RA, Hartley CA, Smith KA, McNiece IK. Recombinant rat SCF synergizes with recombinant human G-CSF in vivo to mobilize PBPCs which have enhanced repopulating potential. Blood 1993; 82: 1720-1723.
34. Crawford J, Lau D, Erwin R, Rich B, McGuire B, Meyers F. A phase I trial of recombinant methionyl human stem cell factor (SCF) with advanced non-small cell lung carcinoma. Proc Amer Soc Clin Oncol 1993; 12: 135.
35. Shpall EJ, Stemmer SM, Bearman SI et al. New strategies for breast cancer patients receiving high-dose therapy with autologous bone marrow transplantation. Breast Cancer Res Treat 1993; 26: S19-23.
36. Sharp JC, Kessinger A, Mann S et al. Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Int J Cell Cloning 1992; 10(Suppl 1): 92.
37. Ross AA, Cooper BW, Lazarus H et al. Incidence of tumor cell contamination in peripheral blood stem cell (PBSC) collections from breast cancer patients. Proc Am Soc Clin Oncol 1993; 12: 68.
38. Moss TJ, Ross AA. The risk of tumor cell contamination in peripheral blood stem cell collections. J of Hematotherapy 1992; 1: 225-232.
39. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380-383.
40. Brenner M, Mirro J Jr, Hurwitz C et al. Gene-marking to trace the origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
41. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
42. Gribben JC. Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325:1525.
43. Yeager A, Kaizer H, Santos GW et al. Autologous bone marrow transplantation in patients with acute non-lymphoblastic leukemia using ex vivo marrow treatment with 4-hydroperocyclophosphamide. N Engl J Med 1986; 315: 141-147.
44. Gorin NC. High-dose therapy for acute myelocytic leukemia. In: Armitage JO, Antman KH, eds. High-Dose Cancer Therapy. Baltimore, MD: Williams and Wilkins, 1995: 635-678.
45. Shpall EJ, Jones RB, Bast RC et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 1991; 9: 85-93.
46. Andrews RG, Singer JW, Bernstein ID. Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 1986; 67: 842-845.
47. + marrow cells engraft lethally irradiated baboons. J Clin Invest 1988; 81: 951-955.
48. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
49. Cagnoni PJ, Jones RB, Franklin W et al. Use of CD34-positive autologous hematopoietic progenitors to support patients with breast cancer after high-dose chemotherapy. Blood 1995; 86: 386a.
50. Franklin WA, Shpall EJ, Archer P et al. Immunohistochemical detection and quantitation of metastatic breast cancer in human bone marrow and peripheral blood. In press.
51. 4 bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995; 85: 1647-1654.
52. Shpall EJ, Gehling U, Cagnoni P, Purdy M, Hami L, Gee A. Isolation of CD34-positive hematopoietic progenitor cells. Immunomethods 1994; 5: 197-203.
53. + cells reconstitute hematopoiesis. Proc Am Soc Clin Oncol 1995; 14: 437.
54. Tricot G, Gazzit Y, Jagannath S, et al. CD34+THY+LIN-peripheral blood stem cells effect timely trilineage engraftment in multiple myeloma. Blood 1995; 86: 293a.
55. Kessinger A, Smith DM, Strandford SE et al. Allogeneic transplantation of blood-derived T-cell depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 643.
56. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
57. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
58. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by Filgrastim (Granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
59. Brown RA, Adkins D, Goodnough T et al. Allogeneic peripheral blood progenitor cell transplant does not appear to increase the risk of acute graft versus host disease following HLA identical sibling transplant. Blood 1995; 86: 393a.
60. Urbano-Ispizua A, Garcia-Conde J, Brunet S et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of short term engraftment and acute GVHD in 33 cases. Blood 1995; 86: 394a.
61. Bishop MR, Tarantolo SR, Schmit-Pokorny K et al. Mobilization of blood stem cells from HLA-matched related donors with low dose granulocyte colony-stimulating factor for allogeneic transplantation. Blood 1995; 86: 463a.
62. Anderlini P, Przepiorka D, Khouri I et al. Chronic graft-vs-host disease after allogeneic marrow or blood stem cell transplantation. Blood 1995; 86: 109a.
63. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413-1415.
64. + cells. Blood 1995; 86: 2500-2508.
65. + peripheral blood stem cells in older patients with advanced hematologic malignacy. Blood 1995; 86: 389a.
66. Bensinger WI, Rowley S, Appelbaum FR et al. CD34 selected allogeneic peripheral blood stem cell transplantation in older patients with advanced hematologic malignancies. Blood 1995; 86: 97a.
67. + cells of peripheral blood and marrow from related donors results in prompt engrfatment and low incidence of GVHD in recipients undergoing allogeneic transplantation. Blood 1995; 86: 389a.
68. Cornetta K, Gharpure V, Hromas R et al. Sibling-matched allogeneic bone marrow transplantation using CD34 cells obtained by immunomagnetic bead separation. Blood 1995; 86: 389a.
69. + selected progenitor cells from matched related donors: results of a clinical phase I/II study. Blood 1995; 86: 290a.